The gut microbiota can also influence the activity of the cytotoxic T lymphocyte-associated antigen-4 or programmed death (PD)-1/PD ligand (PD-L) 1 axis by affecting anti-cancer immuno-surveillance and thus immuno-checkpoint inhibitor therapy efficacy (64). The gene discussed is CTLA4; the disease is cancer.